Navigation Links
Daily Intake of 'Yakult' Is Efficacious in Reducing Incidence of Acute Diarrhea in Young Children
Date:8/20/2010

TOKYO, Aug. 20 /PRNewswire/ -- YAKULT HONSHA CO., LTD. announced on August 20 that its collaborative study on the incidence of acute diarrhea with the National Institute of Cholera and Enteric Diseases in Kolkata, India, showed that daily intake of "Yakult" is efficacious in reducing the incidence of diarrhea in young children.

An unprecedented large-scale study, involving 3,585 children residing in an urban slum community in Kolkata, was conducted. As a result, "Yakult" was shown to be efficacious in reducing the incidence of acute diarrhea in young children and the difference was statistically significant. The demonstration that the continued intake of "Yakult" is effective in improving the gastrointestinal symptoms of the general public strongly corroborates the significance of drinking "Yakult."

These results were published on the "Epidemiology and Infection" website and the ePub is available on PubMed.

YAKULT HONSHA is engaged in research on probiotics, which refer to living microorganisms that confer a benefit on the host (people, etc.) by improving the balance of intestinal flora. A representative probiotic strain is Lactobacillus casei strain Shirota (YIT9029), which, in addition to an intestinal regulation action, has been verified in many published papers to have immunoregulatory actions such as helping to suppress the recurrence of superficial bladder cancer and reduce allergy symptoms. Hereafter, YAKULT HONSHA will continue to actively promote research on utilizing the remarkable power of microorganisms for the benefit of people's health.

Overview of Study

The number of children aged 5 years and under that die annually throughout the world is 8.80 million, and the country that has the most deaths is India (approximately 1.83 million children per year). It is reported that diarrhea is the cause in 13% of the deaths in children aged 5 years and under in India (Black RE et al, Lancet. 2010. 375: 1969-1987).

A double-blind randomized controlled field trial involving 3,585 children aged between 1 and 5 years was carried out in Kolkata, India. The participating children were given either "Yakult" or a placebo drink daily for 12 weeks to observe the incidence of acute diarrhea and pathogenic microbes in the stool.

The results showed that the proportion of children suffering from diarrhea was significantly lower in the "Yakult" group (608 out of 1,802) compared to the placebo group (674 out of 1,783). Moreover, the incidence of diarrhea was lower in the "Yakult" group (0.88/child/year) compared to the placebo group (1.029/child/year) and the difference was statistically significant (p less than 0.01). The analysis of pathogenic bacterial, viral and parasitic agents in the children with diarrhea resulted in the lower detection rate of Aeromonas spp and Cryptosporidium spp in the Yakult group compared to the placebo group.

*The placebo drink did not contain Lactobacillus casei strain Shirota. The taste and color of both the placebo drink and "Yakult" were similar. By comparing the effects of intake of each drink, the efficacy of "Yakult" can be scientifically measured.Contact:  Isamu Sasaoka  PR Department  YAKULT HONSHA CO., LTD.  Phone: +81-3-3574-8920 (Japanese and English Only)  E-mail: strain-shirota@yakult.co.jp (Japanese and English Only)  URL: http://www.yakult.co.jp/english/index.html  Michael Eric D. S. Ong  YAKULT PHILIPPINES, INC.  Phone: +63-2-521-1722  E-mail: micong@yakult.com.ph  Kuek Kok Ti  PR & Advertising Dept.  YAKULT (SINGAPORE) PTE., LTD.  Phone: +65-6756-1033  E-mail: yakult@pacific.net.sg  Dinah Woon  PR Dept.  YAKULT AUSTRALIA PTY. LTD.  Phone: +61-3-9238-4700  E-mail: dwoon@yakult.com.au  Mazlyn Mena binti Mustapha  PR & Science Dept.  YAKULT (MALAYSIA) SDN. BHD.  Phone: +60-3-5569-8960  E-mail: customerservice@yakult.com.my  Shefali Sapra  Corporate Communications  YAKULT DANONE INDIA PRIVATE LIMITED  Phone: +91-11-4062-6262  E-mail: shefali.sapra@yakult.co.in  Yasumi Kimura  R&D Dept.  YAKULT S/A IND. E. COM.  Phone: +55-11-5584-4700  E-mail: yasumi.kimura@yakult.com.br  Jiang Haitian  PR Department  Yakult (China) Corporation  Phone: +86-21-5010-8358  E-mail: jiang-haitian@yakult.com.cn
'/>"/>

SOURCE YAKULT HONSHA CO., LTD.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. New Phase 3 Study in Treatment-Naive Adults with HIV Evaluates Efficacy and Safety of Once-Daily PREZISTA(TM)/ritonavir vs. KALETRA(R) as Part of HIV Combination Therapy
2. New Data Published in Neurology Show Once-Daily Lamictal XR Significantly Reduced Partial Seizures in Patients with Epilepsy
3. Health Canada Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/ tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for HIV
4. Potent Hepatitis C Virus Inhibitors Show Efficacy and Potential for Once Daily Dosing in Preclinical Studies
5. ISTA Pharmaceuticals Presents Results from Two Phase III Clinical Trials of Xibrom(TM) QD (Once-daily) Formulation at the American Academy of Ophthalmology Annual Meeting
6. Post-Hoc Data Show Daily Activity Participation, Independence and Sleep Quality Improved in Adults with Moderate to Severe Rheumatoid Arthritis After Treatment with ORENCIA(R) (Abatacept)
7. Voices to Unite in Los Angeles for 6,000 Children Orphaned Daily
8. European Commission Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for Virologically Suppressed Adults With HIV-1 Infection
9. Anthera Announces Preliminary Positive Results From Once-Daily A-002 Phase II Cardiovascular Trial
10. CASTLE Study Showed Similar Efficacy Between Once-Daily REYATAZ(R) (atazanavir sulfate)/ritonavir and Twice-Daily lopinavir/ritonavir at 48 Weeks in Previously Untreated HIV-Infected Adult Patients
11. U.S. Census Bureau Daily Feature for March 11
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/5/2016)... , Feb. 5, 2016 Dehaier Medical ... or the "Company"), which develops, markets and sells ... China and international markets, ... which aims to concentrate the Company,s resources to ... respiratory business and to focus more on its ...
(Date:2/5/2016)... 2016  Henry Schein, Inc. (NASDAQ: HSIC ), the ... to office-based dental, animal health and medical practitioners, announced ... acquire a majority ownership interest in Dental Cremer S.A., ... Brazil . --> ... is the dental distribution business of Cremer S.A. With ...
(Date:2/5/2016)... DUBLIN , Feb. 5, 2016 /PRNewswire/ ... the addition of the "Global Obstetrics ... company profile to their offering. ... addition of the "Global Obstetrics Partnering ... company profile to their offering. --> ...
Breaking Medicine Technology:
(Date:2/6/2016)... (PRWEB) , ... February 06, 2016 , ... Shark ... to announce the launch of a new DRTV campaign with Belly Bands. , Having ... tried everything from sprays to puppy pads and find nothing works, get Belly ...
(Date:2/5/2016)... ... February 05, 2016 , ... Steven Tonkinson, 36, of Coconut Grove, ... year since it started in 2003. This year, he ran all 26.2 miles with ... and NBA team the Miami Heat. , This Sunday, while many are watching the ...
(Date:2/5/2016)... , ... February 05, 2016 , ... ... availability of the company's lighter, sleeker next generation LYNX VR Indoor Trainer with ... , Improvements in design and manufacturing not only reduce the weight of the ...
(Date:2/5/2016)... , ... February 05, 2016 , ... ... setting the stage for new clinical and scientific initiatives have all marked the ... she was appointed President and CEO of the nation’s oldest cancer center, Candace ...
(Date:2/5/2016)... ... February 05, 2016 , ... ... franchisees of Popeyes Louisiana Kitchen restaurants, launched the 14th annual “Appetite for a ... and adults with muscular dystrophy, ALS and related diseases that severely limit strength ...
Breaking Medicine News(10 mins):